J&J Deal With Metabolex Brings Late-Stage Diabetes Candidate To Pipeline
This article was originally published in The Pink Sheet Daily
Executive SummaryJ&J will pay Metabolex $40 mil. for rights to the Phase II/III insulin sensitizer metaglidasen and other investigational drugs.
You may also be interested in...
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.